Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Alexander Roeth, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Marc Michel, Quentin A. Hill, Shruti Srivastava, Ronnie Yoo, Catherine M. Broome

Blood (2023) 142 (Supplement 1): 7341.

https://doi.org/10.1182/blood-2023-180678

Published: 2023

Journal Articles

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Andrew J. Doyle, Matthew J. Stubbs, Tina Dutt, Will Lester, Will Thomas, Joost van Veen, Joannes Hermans, Tanya Cranfield, Quentin A. Hill, Amanda Clark, Catherine Bagot, Steven Austin, John-Paul Westwood, Mari Thomas, Marie Scully

Blood (2023) 141 (3): 285–294.

https://doi.org/10.1182/blood.2022017023

Published: 2023

Journal Articles

Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Catherine M. Broome, Wilma Barcellini, Alexander Roeth, Alia Karaouni, Florence Joly, Ronnie Yoo, Augustin Terlinden, Ayo Adeyemi, Yola Moride, Quentin A. Hill

Blood (2022) 140 (Supplement 1): 5306–5308.

https://doi.org/10.1182/blood-2022-163232

Published: 2022

Journal Articles

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Alexander Roeth, Catherine M. Broome, Wilma Barcellini, Bernd Jilma, Quentin A. Hill, David Cella, Tor Henrik Anderson Tvedt, Masaki Yamaguchi, Irina Murakhovskaya, Michelle Lee, Frank Shafer, Marek Wardecki, Jennifer Wang, Ronnie Yoo, Jerome Mshijid, Ilene C. Weitz

Blood (2022) 140 (Supplement 1): 70–72.

https://doi.org/10.1182/blood-2022-159966

Published: 2022

Journal Articles

The Psychometric Properties of the ITP Life Quality Index Assessed in a Large Multinational "Real-World" Cohort of Immune Thrombocytopaenia Patients

Philip Griffiths, Laura Grant, Nicola Bonner, MSc, Denise D'Alessio, MBA, Quentin A. Hill, Drew Provan, MD, Waleed Ghanima, MD PhD, Nichola Cooper, MD MRCP, Ricardo Viana, PhD

Blood (2019) 134 (Supplement_1): 386.

https://doi.org/10.1182/blood-2019-125766

Published: 2019

Journal Articles

Mortality Among Patients with Cold Agglutinin Disease in the United States: An Electronic Health Record (EHR)-Based Analysis

Quentin A. Hill, Rajeshwari Punekar, Jaime Morales Arias, Catherine M Broome, MD, Jun Su

Blood (2019) 134 (Supplement_1): 4790.

https://doi.org/10.1182/blood-2019-122140

Published: 2019

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

Blood (2019) 133 (15): 1644–1651.

https://doi.org/10.1182/blood-2018-11-884700

Published: 2019

Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 736.

https://doi.org/10.1182/blood-2018-99-110482

Published: 2018

Journal Articles

Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study

Nichola Cooper, MRCP, Andrew Provan, Marie Scully, MD MRCP, FRCPath, Henri Grech, Catherine Bagot, MD FRCPath, MBBS, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Tim Nokes, Nicholas Ramscar, Luke Saunders

Blood (2018) 132 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2018-99-110126

Published: 2018

Journal Articles

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

Blood (2017) 130 (4): 466–471.

https://doi.org/10.1182/blood-2016-12-758656

Published: 2017

Journal Articles

How does dapsone work in immune thrombocytopenia? Implications for dosing

Quentin A. Hill

Blood (2015) 125 (23): 3666–3668.

https://doi.org/10.1182/blood-2015-03-632000

Published: 2015

Journal Articles

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Quentin A. Hill, Andy C. Rawstron, Ruth M. de Tute, Roger G. Owen

Blood (2014) 124 (8): 1296–1299.

https://doi.org/10.1182/blood-2014-04-566521

Published: 2014

Journal Articles

Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.

Quentin A. Hill, MD, Ruth M. de Tute, MSc, J. Anthony Child, MD, Andy C. Rawstron, PhD, Roger G. Owen, MD

Blood (2006) 108 (11): 3512.

https://doi.org/10.1182/blood.V108.11.3512.3512

Published: 2006

Journal Articles

Survival of Patients with Hematological Malignancy Admitted to the Intensive Care Unit (ICU): Prognostic Factors and Outcome Compared to Unselected Medical ICU Admissions.

Quentin A. Hill, MD, Anita Hill, MD, Richard Kelly, MD, Chetan Patalappa, MD, Annika M. Whittle, MD, Andrew J. Scally, MSc, Anthony Hughes, MD, John Ashcroft, MD, PhD

Blood (2006) 108 (11): 3319.

https://doi.org/10.1182/blood.V108.11.3319.3319

Published: 2006

Journal Articles

The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.

Anita Hill, MD, Philip J. Platts, MRes, Alex Smith, PhD, Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Quentin A. Hill, MD, Eve Roman, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 985.

https://doi.org/10.1182/blood.V108.11.985.985

Published: 2006

NARROW

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

The Psychometric Properties of the ITP Life Quality Index Assessed in a Large Multinational "Real-World" Cohort of Immune Thrombocytopaenia Patients

Mortality Among Patients with Cold Agglutinin Disease in the United States: An Electronic Health Record (EHR)-Based Analysis

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

How does dapsone work in immune thrombocytopenia? Implications for dosing

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.

Survival of Patients with Hematological Malignancy Admitted to the Intensive Care Unit (ICU): Prognostic Factors and Outcome Compared to Unselected Medical ICU Admissions.

The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only